Corona Remedies Ltd management interview: Corona Remedies Beats Its Growth Guidance? CFO Reveals What's Next For FY27 | Business News | ET Now
ET Now, 2026-11-02. Video: https://www.youtube.com/watch?v=rx6httWezBw
- Therapy growth: Women’s healthcare, cardio-diabeto, pain management and urology contribute 70% of revenue, and their growth is almost double the Indian pharmaceutical market’s growth.
- Growth drivers: Volume and new introductions account for 60% of total growth; the company reported 22.5% growth against 12% for the IPM. NLEM pricing is 7.75% against the IPM’s 16%, leaving room for price increases.
- Portfolio strategy: Corona deliberately shifted from a mix of 30% chronic and 70% acute to a greater focus on chronic therapies, which management described as a stickier business. Of 81 brands, 33 are “engine brands” with potential to cross 100 crore; they contribute 80% of revenue and have grown by 22% over the last 3 years.
- FY27 outlook: Management said it is ahead of its guidance of 15% revenue growth and 20% PAT growth, and is eyeing 1.5x growth on the revenue side. It expects margins to be north of 20% for FY27.